Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference
February 01 2022 - 8:00AM
Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage
company developing transformative therapies for the treatment of
cancer and rare diseases, today announced that management will
participate in a virtual fireside chat at the Guggenheim Healthcare
Talks 2022 Oncology Conference on February 9,
2022 at 4:00 PM ET.
A live webcast of the fireside chat can be
accessed by visiting the Events and Presentations section of the
Company’s website: https://ir.protaratx.com. The webcast will be
archived on the Company’s website for 90 days following the
presentation.
About Protara
Therapeutics, Inc.
Protara is committed to identifying and
advancing transformative therapies for people with cancer and rare
diseases with limited treatment options. Protara’s portfolio
includes its lead program, TARA-002, an investigational cell-based
therapy being developed for the treatment of non-muscle invasive
bladder cancer and lymphatic malformations, and IV Choline
Chloride, an investigational phospholipid substrate replacement
therapy for the treatment of intestinal failure-associated liver
disease. For more information, visit www.protaratx.com.
Company Contact:
Justine O'MalleyProtara
TherapeuticsJustine.OMalley@protaratx.com646-817-2836
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Jul 2023 to Jul 2024